past events
- 2023-
- ASA New Jersey/Princeton-Trenton Chapters Joint Symposium
- Utilities of 2-Stage Designs for Addressing Dose Optimization in Pivotal Trials
- OPTIM-ARTS An Adaptive Phase II Open Platform Trial Design
- Adaptive Multi-arm Multi-stage Designs
- Recommendations for Multi-Arm Umbrella Trials and Platform Trials
- An Introduction to the Use of Graphical Testing Procedures in Group-Sequential Designs
- A generalized framework of Optimal two-stage designs for exploratory basket trials
- Poster: Leveraging Cloud Computing and Advanced Software for Trial Optimization
- ASA New Jersey/Princeton-Trenton Chapters Joint Symposium
- 2022-
- ASA New Jersey/Princeton-Trenton Chapters Joint Symposium
- Dose optimization in oncology drug development: Where we are and how we got here
- Pragmatic and Holistic Approach for Dose Finding and Optimization in Oncology Drug Development – A Clinical Pharmacology Point of View
- A Practical and Holistic approach for Dose Selection in Cancer Drug Development
- On the efficiency of the hybrid testing-modeling approach for binary responses
- Bayesian adaptive designs for dose optimization
- ASA New Jersey Chapter and Bayer Statistics and Data Insights 9th joint Annual Workshop
- Please click HERE for the slides
- ASA NJ Chapter Webinar
- Combining the target trial and estimand frameworks to define the causal estimand: an application using real-world data to contextualize a single-arm trial
- Benefits of target trial and estimand frameworks in real-world evidence of treatment effects for supporting health technology assessment
- Introduction to the ICH E9(R1) estimand and target trial emulation frameworks, and their role in the design and analysis of RWE studies
- External control arms in oncology: current use and future directions?
- Applying the Estimand and Target Trial frameworks to external control analyses using observational data: a case study in the solid tumor setting
- Event Free Survival in the Light of the Lymphoma Patient Journey: What do We Really Want to Measure?
- Applying the Estimand Framework to High-Risk Non-Muscle Invasive Bladder Cancer Trials: Considerations for Populations with Carcinoma in Situ (CIS) and Papillary Disease
- ASA New Jersey/Princeton-Trenton Chapters Joint Symposium
- 2021-
- ASA NJ Chapter and Biopharmaceutical Section joint Webinar
- Annual ASA NJ Chapter/Bayer Statistics Workshop
- 2020-
- ASA NJ Chapter Sponsored Webinar
- Statistical Considerations for Development of Novel Combination Designs for Immuno-Oncology Development
- Statistical Challenges in Designing Combination-Therapy Trials in Oncology
- Examining horseshoe prior and knockoffs for variable selection problems in drug development
- An adaptive-flavored group sequential design with connection to conditional error
- Statistical Concerns for the Analysis of Data Collected by Wearable Digital Health Technology in Clinical Trials
- Monitor On-Going Clinical Trials with a Dynamic Procedure
- Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis
- Statistical Considerations in the Design of COVID-19 Vaccine Trials Using Real-World Data and Evidence
- ASA NJ Chapter Sponsored Webinar